BioMarin Pharmaceuticals
BMRN
313 hedge funds and large institutions have $10.4B invested in BioMarin Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 119 increasing their positions, 109 reducing their positions, and 35 closing their positions.
31% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 35
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
2% more funds holding
Funds holding: 306 → 313 (+7)
9% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 109
5% more capital invested
Capital invested by funds: $9.95B → $10.4B (+$450M)
10% less call options, than puts
Call options by funds: $116M | Put options by funds: $128M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$355M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$216M |
| 3 |
Temasek Holdings
Singapore
|
+$114M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$66.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$52.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$101M |
| 2 |
Millennium Management
New York
|
-$67.5M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$48.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$47.1M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$42.8M |
BMRN Hedge Fund Activity: Q1 2014 in Review
313 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2014, worth a combined $10.4B — up 4.5% from $9.95B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new BMRN positions and 35 closed out — a net gain of 11 holders — while 119 added to existing stakes and 109 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $355M. The largest seller was Jennison Associates, cutting an estimated $101M.
- 313 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2014, up from 306 in Q4 2013.
- Funds reported $10.4B of BioMarin Pharmaceuticals stock for Q1 2014, up 4.5% quarter-over-quarter.
- 46 funds opened new BioMarin Pharmaceuticals positions in Q1 2014 and 35 closed out, a net change of +11 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2014 was Winslow Capital Management, an estimated $355M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2014 was Jennison Associates, an estimated $101M sold.
Based on aggregated 13F filings for Q1 2014.